Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06237335 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
A Phase 2 study of Cystic Fibrosis, sponsored by ReCode Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
- 20
- Study locations
NCT06237335: Recruiting Phase 2 study of Cystic Fibrosis, sponsored by ReCode Therapeutics.
NCT06237335 is a Phase 2 study of Cystic Fibrosis that is actively recruiting participants, run by ReCode Therapeutics. The registered enrollment target is 192 participants, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06237335, a Phase 2 study of Cystic Fibrosis, is actively recruiting participants, sponsored by ReCode Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
Primary Outcome
Safety and tolerability as assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ivacaftor
- DRUG RCT2100
Study Locations (20)
Other
- Centre Hospitalier Régional Universitaire de Montpellier - Hôpital Arnaud de Villeneuve - Montpellier
- Hôpital Necker Enfants Malades - Paris
- UMC Utrecht - Utrecht
- New Zealand Clinical Research (Part 1 Only) - Auckland
- University Hospitals Birmingham - Birmingham
- Royal Papworth Hospital - Cambridge
- Leeds Teaching Hospitals - Leeds
California
- Stanford University - Palo Alto
- UCSD - San Diego
Alabama
- The University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona - Tucson
Colorado
- National Jewish Health - Denver
Georgia
- Emory University - Atlanta
Massachusetts
- Boston Children's Hospital - Boston
New York
- New York Medical College - Valhalla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2024-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What NCT06237335 shows while recruiting
NCT06237335 is an interventional study that assigns participants to a tested intervention. The registered 192 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 178-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06237335 names 20 study sites across 13 states, led by Other, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT06237335 about?
NCT06237335 is a clinical study titled "A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF". This is the first-in-human study with RCT2100 and is designed to provide safety and tolerability data for future clinical studies.
What is the current status of trial NCT06237335?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2024-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06237335 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT06237335?
The interventions under investigation include: Placebo (OTHER), Ivacaftor (DRUG), RCT2100 (DRUG).
Who is sponsoring clinical trial NCT06237335?
This trial is sponsored by ReCode Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06237335 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06237335's enrollment target sits among peer trials
192 37th of 169 higher than 133 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
-
Nasal Potential Studies Utilizing Cystic Fibrosis Transmembrane Regulator (CFTR) Modulators
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492972 · 192 participants · Phase 3
Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
- NCT01973881 · 192 participants
Quantitative MRI for Myelofibrosis
- NCT02535702 · 192 participants · NA
Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction
- NCT03622359 · 192 participants · NA
Radiotracer-Based Perfusion Imaging of Patients With Peripheral Arterial Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI